Portal hypertension has high morbidity and mortality, and upper gastrointestinal bleeding is its most harmful complication and the main cause of death, accounting for 39.5% of deaths from cirrhosis alone; in clinical work, doctors in various disciplines have difficulty in finding good solutions to portal hypertension, and with the development of material synthesis technology and interventional medicine, radiological interventional treatment of portal hypertension can often have an unexpected effect. I. Prehepatic: 1. portal thrombosis 2. portal tumor compression: pancreatic head cancer, pancreatic pseudocyst 3. congenital malformation: portal spongiform transformation. Liver diseases: post-hepatitis B cirrhosis (>90%, 10-20% incidence of hepatitis B in China), alcoholic cirrhosis (common in Europe and the United States), schistosomiasis (middle and lower reaches of Yangtze River), congenital diseases of the liver (glycogen accumulation disorder), etc. Third, posthepatic: 1, Budd Chiari syndrome 2, severe right heart failure dual intervention: percutaneous hepatic perforation of the gastric coronary vein embolization + partial splenic artery embolization? Percutaneous hepatic perforation of gastric coronary vein embolization – percutaneous hepatic perforation of intrahepatic portal branches, selective embolization of varices in the fundus and lower esophagus to treat bleeding esophageal varices; partial splenic embolization – is partial splenic artery embolization via catheter? Interventional flow dissection therapy can simultaneously embolize the variceal plexus of the esophagogastric fundus and part of the splenic parenchyma to truly achieve “non-surgical flow dissection”, thus reducing the filling of the collateral circulation, reducing portal blood flow, and also relieving hypersplenic symptoms and preserving the normal function of the spleen. It has good safety, low morbidity and mortality rate, precise immediate hemostatic effect, low rebleeding rate, simple operation and easy to promote, especially for elderly patients with long medical history, severe disease, poor physical condition and poor tolerance, the 5-year productivity is 66.0, the 5-year cumulative rebleeding rate is 44.1, and the median survival is 78.6 months.